Linus Health Earns Medical Device Regulation Certification in the European Union
EU MDR Class IIa certification of Core Cognitive Evaluation™ designates the solution is determined safe, effective, and compliant with laws
"The growth of dementia is a significant public health problem across the world," said Linus Health Chief Medical Officer Alvaro Pascual-Leone, MD, PhD. "Earning EU class IIa MDR certification allows us to expand our offering in the EU beyond assessment to include clinical decision support, which is critical in supporting clinicians to navigate next steps, consider concrete actionable recommendations, and connect patients with the right care and clinical interventions that have been shown to delay or even prevent the onset of dementia due to Alzheimer's disease or other causes."
Linus Health's CCE gives primary care, specialists, and researchers a highly accurate digital cognitive assessment that is brief, easy to administer and brings visibility to early cognitive impairment. It combines objective analysis of cognitive performance with qualitative metrics to deliver brain health insights and a customized action plan to treat the disease.
To learn more about Linus Health's complete platform of cognitive health digital assessments, click here.
About Linus Health
Linus Health is a
Media Contact
Amendola for Linus Health (
+14402259595
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/linus-health-earns-medical-device-regulation-certification-in-the-european-union-302331824.html
SOURCE Linus Health
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BEAR NutriEase Baby Food Maker Stands Out With a Stainless Steel Design in a Plastic-Dominated Category
- Title: Grace Legal Group Expands Criminal Defense Services Across Los Angeles County
- Scripps Local Broadcast Stations Return to DIRECTV
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share